Drugs / Fosrolapitant
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05465681 | Aug 2022 → Jan 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07841210 | Sep 2026 → Jan 2028 expected | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07692451 | Jul 2026 → Jul 2027 expected | chemotherapy-induced toxicity | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07617246 | Nov 2025 → Jan 2027 expected | esophageal cancer, lung cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07482891 | Mar → Oct 2026 expected | chemotherapy-induced toxicity | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07848984 Background | Oct 2026 → Aug 2028 expected | breast neoplasm | Second Affiliated Hospital, Zhejiang University, School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fosrolapitant | “BACKGROUND: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and...” PMID 40866861 ↗ Aug 20255“NK-1 receptor antagonists may include fosrolapitant, aprepitant, or fosaprepitant.” NCT07848984 ↗ |
| Modality | Small molecule | — CHEMBL6068054 ↗ |
| Route | Intravenous | “Intravenous drip for 1 hour (+10 minutes)” NCT07617246 ↗ |